These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 12137117

  • 1. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117
    [No Abstract] [Full Text] [Related]

  • 2. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F.
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].
    Arai H, Minami J.
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):313-9. PubMed ID: 17938518
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.
    Mov Disord; 2002 Oct; 17 Suppl 4():S98-102. PubMed ID: 12211149
    [No Abstract] [Full Text] [Related]

  • 10. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
    Marek K, Jennings D, Seibyl J.
    Ann Neurol; 2003 Oct; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Dopamine agonists in the management of Parkinson disease. D1- and D2-receptors regulate the motor function].
    Nervenarzt; 1994 Jul; 65(7 Suppl Dopaminago):1-4. PubMed ID: 9431361
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Current pharmacotherapy of Parkinson's disease].
    Takáts A.
    Orv Hetil; 2000 Mar 05; 141(10):483-8. PubMed ID: 10750400
    [Abstract] [Full Text] [Related]

  • 16. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE.
    Mov Disord; 2004 May 05; 19(5):491-8. PubMed ID: 15133811
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease.
    Pirtosek Z, Merello M, Carlsson A, Stern G.
    Adv Neurol; 1996 May 05; 69():535-40. PubMed ID: 8615177
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.